Ascendis Pharma A/S (NASDAQ:ASND) Upgraded at BidaskClub

Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a report issued on Wednesday, December 27th.

ASND has been the topic of a number of other reports. Wells Fargo & Co reissued a “buy” rating and issued a $51.00 price target on shares of Ascendis Pharma A/S in a research report on Friday, September 22nd. Bank of America lowered their price objective on Ascendis Pharma A/S from $46.00 to $43.00 and set a “buy” rating on the stock in a research report on Friday, November 17th. Credit Suisse Group reaffirmed an “outperform” rating and issued a $50.00 price objective (up from $30.00) on shares of Ascendis Pharma A/S in a research report on Friday, September 22nd. Wedbush reaffirmed an “outperform” rating and issued a $10.71 price objective (down from $65.00) on shares of Ascendis Pharma A/S in a research report on Friday, September 22nd. Finally, Leerink Swann reaffirmed a “hold” rating and issued a $28.00 price objective on shares of Ascendis Pharma A/S in a research report on Friday, September 1st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company. Ascendis Pharma A/S currently has an average rating of “Buy” and a consensus target price of $38.79.

Shares of Ascendis Pharma A/S (NASDAQ:ASND) opened at $45.63 on Wednesday. Ascendis Pharma A/S has a 12-month low of $19.95 and a 12-month high of $47.71. The company has a market capitalization of $1,660.00 and a P/E ratio of -11.61.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Bank of America Corp DE raised its stake in Ascendis Pharma A/S by 23.6% during the 1st quarter. Bank of America Corp DE now owns 5,345 shares of the biotechnology company’s stock valued at $150,000 after buying an additional 1,020 shares during the last quarter. Bank of Montreal Can raised its stake in Ascendis Pharma A/S by 127.4% during the 2nd quarter. Bank of Montreal Can now owns 4,535 shares of the biotechnology company’s stock valued at $126,000 after buying an additional 2,541 shares during the last quarter. Alps Advisors Inc. raised its stake in Ascendis Pharma A/S by 9.1% during the 3rd quarter. Alps Advisors Inc. now owns 31,929 shares of the biotechnology company’s stock valued at $1,157,000 after buying an additional 2,665 shares during the last quarter. California Public Employees Retirement System raised its stake in Ascendis Pharma A/S by 26.8% during the 3rd quarter. California Public Employees Retirement System now owns 19,658 shares of the biotechnology company’s stock valued at $713,000 after buying an additional 4,158 shares during the last quarter. Finally, Victory Capital Management Inc. purchased a new stake in Ascendis Pharma A/S during the 3rd quarter valued at $194,000. Institutional investors and hedge funds own 78.93% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Ascendis Pharma A/S (NASDAQ:ASND) Upgraded at BidaskClub” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/12/ascendis-pharma-as-asnd-upgraded-to-buy-at-bidaskclub.html.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply